{Reference Type}: Journal Article
{Title}: TATA-Binding Protein-Based Virtual Screening of FDA Drugs Identified New Anti-Giardiasis Agents.
{Author}: Gaona-López C;Méndez-Álvarez D;Moreno-Rodríguez A;Bautista-Martínez JL;De Fuentes-Vicente JA;Nogueda-Torres B;García-Torres I;López-Velázquez G;Rivera G;
{Journal}: Int J Mol Sci
{Volume}: 25
{Issue}: 11
{Year}: 2024 Jun 5
{Factor}: 6.208
{DOI}: 10.3390/ijms25116238
{Abstract}: Parasitic diseases, predominantly prevalent in developing countries, are increasingly spreading to high-income nations due to shifting migration patterns. The World Health Organization (WHO) estimates approximately 300 million annual cases of giardiasis. The emergence of drug resistance and associated side effects necessitates urgent research to address this growing health concern. In this study, we evaluated over eleven thousand pharmacological compounds sourced from the FDA database to assess their impact on the TATA-binding protein (TBP) of the early diverging protist Giardia lamblia, which holds medical significance. We identified a selection of potential pharmacological compounds for combating this parasitic disease through in silico analysis, employing molecular modeling techniques such as homology modeling, molecular docking, and molecular dynamics simulations. Notably, our findings highlight compounds DB07352 and DB08399 as promising candidates for inhibiting the TBP of Giardia lamblia. Also, these compounds and DB15584 demonstrated high efficacy against trophozoites in vitro. In summary, this study identifies compounds with the potential to combat giardiasis, offering the prospect of specific therapies and providing a robust foundation for future research.